ERBB2 and triple-negative breast carcinoma: Interestingly, the cytotoxic effect of T-DM1 in the FMCp cell line presented promising results, 74.2% of cytotoxicity being obtained, which could be explained by the axis DM-1/cytoskeleton-associated protein 5 (CKAP5) a microtubule regulator protein, cell surface target for T-DM1, inducing cytotoxicity in no HER2-overexpressing cells [78], suggested as a target in triple-negative breast cancer therapy [79].